<DOC>
	<DOCNO>NCT02960438</DOCNO>
	<brief_summary>This study multicenter , randomize , double-blind , placebo-controlled , parallel-group comparison study rheumatoid arthritis participant inadequately respond methotrexate .</brief_summary>
	<brief_title>A Dose Response Study E6011 Subjects With Rheumatoid Arthritis Inadequately Responding Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Aged ≥18 &lt; 75 year old time inform consent Diagnosed rheumatoid arthritis ( RA ) 1987 American College Rheumatology ( ACR ) 2010 ACR/European League Against Rheumatism ( EULAR ) criteria ≥12 week inform consent Received methotrexate ( MTX ) treatment 6 16 milligram ( mg ) /week ≥12 week screen present ≥6 tender joint ( 68 joint ) ≥6 swollen joint ( 66 joint ) Screening Observation Phases Can continue stable dose regimen MTX 6 16 mg/week 4 week start study treatment completion Extension Phase ( study discontinuation ) Creactive protein ( CRP ) level ≥0.6 mg/deciliter ( dL ) erythrocyte sedimentation rate ( ESR ) ≥28 millimeter per hour ( mm/hr ) Screening Phase Erosions ≥3 sit radiographic image Screening Phase , erosion ≥1 site either positive rheumatoid factor ( RF ) anticyclic citrullinated peptide ( CCP ) antibody Screening Phase Weighs ≥30 kilogram ( kg ) ≤100 kg Screening Phase Has voluntarily consent , write , participate study . If participant age 20 , also consent , write , legally acceptable representative . Has thoroughly brief condition participation study , able understand , willing able comply aspect protocol Any history complication inflammatory arthritic disorder RA Sjogren 's syndrome Meets ACR 1991 Revised Criteria Classification Global Functional Status RA Class IV Screening Phase Received immunoglobulin preparation blood product within 24 week start study treatment Received live vaccine within 12 week start study treatment , plan receive Evidence clinically significant disease ( e.g. , cardiac , respiratory , gastrointestinal , renal disease ) could affect participant 's safety interfere study assessment opinion investigator subinvestigator Complication uncontrolled disorder acute cardiac infarction , unstable angina , brain infarct , symptomatic intracerebral hemorrhage History severe allergy ( shock anaphylactoid symptom ) History current clinical condition malignant tumor , lymphoma , leukemia , lymphoproliferative disease , except skin carcinoma ( epithelial carcinoma basal cell carcinoma ) cervix carcinoma completely excise without metastasis recurrence 5 year informed consent Immunodeficiency history human immunodeficiency virus ( HIV ) infection Infection require hospitalization intravenous administration antibiotic disease require administration antivirus drug ( e.g. , herpes zoster ) within 4 week start study treatment History tuberculosis current complication active tuberculosis History clinically important vasculitis Tested positive follow Screening Phase : HIV , hepatitis B virus surface antigen ( HBs antigen ) , hepatitis B virus surface antibody ( HBs antibody ) , hepatitis B virus core antibody ( HBc antibody ) , hepatitis B virus deoxyribonucleic acid ( HBV DNA ) , hepatitis C virus antibody ( HCV antibody ) , human Tlymphotrophic virus Type I antibody ( HTLV1 antibody ) , syphilis Positive tuberculosis test ( QuantiFERON®TB Gold Test TSPOT®.TB Test ) Screening Phase Findings indicate history tuberculosis chest xray Screening Phase Neurological finding paralysis , visual impairment , language disorder Screening Phase Demonstrated prolong QTcF interval ( &gt; 450 millisecond [ m ] ) repeat electrocardiogram examination Females childbearing potential positive pregnancy test Screening Observation Phase breastfeed Females childbearing potential : Had unprotected sexual intercourse within 30 day study entry agree use highly effective method contraception ( e.g. , total abstinence , intrauterine device , doublebarrier method [ condom plus diaphragm spermicide ] , contraceptive implant , oral contraceptive , vasectomized partner confirm azoospermia ) throughout entire study period 28 day study drug discontinuation Are currently abstinent , agree use doublebarrier method ( describe ) refrain sexually active study period 28 day study drug discontinuation Are use hormonal contraceptive stable dose hormonal contraceptive product least 4 week dose agree use contraceptive study 28 day study drug discontinuation ( NOTE : All female consider childbearing potential unless postmenopausal [ amenorrheic least 12 consecutive month , appropriate age group , without know suspected cause ] sterilize surgically [ i.e. , bilateral tubal ligation , total hysterectomy , bilateral oophorectomy , surgery least 1 month dose ] ) . Males successful vasectomy ( confirm azoospermia ) female partner meet criterion ( i.e. , childbearing potential practicing highly effective contraception throughout study period 28 day study drug discontinuation ) . No sperm donation allow study period 28 day study drug discontinuation . Scheduled surgery study Currently enrol another clinical study use investigational drug device within 28 day ( 5× halflife , whichever long ) inform consent Has treat E6011 biologics use RA approve Use psychotropic agent recreational purpose therapeutic purpose Any history medical condition concomitant medical condition opinion investigator subinvestigator would compromise participant 's ability safely complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>E6011</keyword>
	<keyword>rheumatoid arthritis</keyword>
</DOC>